| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 108 | 2023 | 1202 | 22.950 |
Why?
|
| Colonic Neoplasms | 37 | 2022 | 1390 | 8.550 |
Why?
|
| Colectomy | 24 | 2022 | 288 | 6.230 |
Why?
|
| Colorectal Neoplasms | 48 | 2024 | 3578 | 5.220 |
Why?
|
| Lymph Node Excision | 25 | 2023 | 1959 | 4.790 |
Why?
|
| Neoadjuvant Therapy | 50 | 2023 | 4975 | 4.750 |
Why?
|
| Digestive System Surgical Procedures | 18 | 2022 | 275 | 3.920 |
Why?
|
| Chemoradiotherapy | 28 | 2023 | 1946 | 3.660 |
Why?
|
| Robotic Surgical Procedures | 11 | 2023 | 481 | 3.570 |
Why?
|
| Adenocarcinoma | 45 | 2023 | 7789 | 3.510 |
Why?
|
| Neoplasm Recurrence, Local | 59 | 2024 | 10035 | 3.170 |
Why?
|
| Neoplasm Staging | 88 | 2023 | 13658 | 2.730 |
Why?
|
| Laparoscopy | 15 | 2023 | 1225 | 2.270 |
Why?
|
| Rectum | 15 | 2023 | 467 | 2.270 |
Why?
|
| Mesenteric Veins | 4 | 2020 | 73 | 2.220 |
Why?
|
| Mesocolon | 3 | 2020 | 4 | 2.200 |
Why?
|
| Lymph Nodes | 17 | 2023 | 2967 | 1.810 |
Why?
|
| Chemoradiotherapy, Adjuvant | 11 | 2020 | 565 | 1.770 |
Why?
|
| Anus Neoplasms | 14 | 2023 | 411 | 1.700 |
Why?
|
| Humans | 256 | 2024 | 261506 | 1.680 |
Why?
|
| Adenocarcinoma, Mucinous | 6 | 2022 | 436 | 1.520 |
Why?
|
| Quality Indicators, Health Care | 4 | 2017 | 348 | 1.380 |
Why?
|
| Pelvis | 7 | 2023 | 362 | 1.340 |
Why?
|
| Quality Assurance, Health Care | 3 | 2020 | 585 | 1.240 |
Why?
|
| Lymphatic Metastasis | 20 | 2022 | 4844 | 1.240 |
Why?
|
| Middle Aged | 118 | 2023 | 86204 | 1.200 |
Why?
|
| Male | 134 | 2023 | 123000 | 1.180 |
Why?
|
| SEER Program | 15 | 2015 | 1000 | 1.170 |
Why?
|
| Margins of Excision | 6 | 2023 | 285 | 1.150 |
Why?
|
| Prognosis | 52 | 2022 | 21713 | 1.150 |
Why?
|
| Aged | 101 | 2021 | 70117 | 1.120 |
Why?
|
| Watchful Waiting | 2 | 2019 | 289 | 1.100 |
Why?
|
| Survival Rate | 43 | 2021 | 12221 | 1.100 |
Why?
|
| Female | 133 | 2023 | 141928 | 1.090 |
Why?
|
| Ileostomy | 2 | 2018 | 46 | 1.070 |
Why?
|
| United States | 43 | 2023 | 15433 | 1.070 |
Why?
|
| Retrospective Studies | 69 | 2023 | 37905 | 1.000 |
Why?
|
| Minimally Invasive Surgical Procedures | 5 | 2018 | 500 | 0.960 |
Why?
|
| Robotics | 3 | 2019 | 359 | 0.950 |
Why?
|
| Insurance, Health | 5 | 2020 | 250 | 0.940 |
Why?
|
| Treatment Outcome | 58 | 2023 | 32848 | 0.940 |
Why?
|
| Societies, Medical | 5 | 2022 | 1335 | 0.900 |
Why?
|
| Medical Oncology | 6 | 2023 | 1423 | 0.890 |
Why?
|
| Patient Selection | 8 | 2022 | 2055 | 0.890 |
Why?
|
| Neoplasms | 16 | 2024 | 15193 | 0.890 |
Why?
|
| Transanal Endoscopic Surgery | 1 | 2022 | 3 | 0.880 |
Why?
|
| Chemotherapy, Adjuvant | 20 | 2023 | 3890 | 0.870 |
Why?
|
| Carcinoma | 7 | 2020 | 2578 | 0.860 |
Why?
|
| Peritoneal Neoplasms | 4 | 2022 | 821 | 0.840 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2020 | 2594 | 0.820 |
Why?
|
| Microsatellite Instability | 3 | 2023 | 400 | 0.820 |
Why?
|
| Length of Stay | 6 | 2017 | 1900 | 0.810 |
Why?
|
| Proportional Hazards Models | 18 | 2022 | 4988 | 0.790 |
Why?
|
| Medicine | 1 | 2023 | 137 | 0.790 |
Why?
|
| Quality of Life | 11 | 2023 | 4532 | 0.780 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2022 | 7702 | 0.780 |
Why?
|
| Colon | 3 | 2020 | 670 | 0.780 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2022 | 107 | 0.770 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2021 | 6207 | 0.770 |
Why?
|
| Surgical Oncology | 3 | 2020 | 190 | 0.730 |
Why?
|
| Combined Modality Therapy | 31 | 2023 | 8865 | 0.720 |
Why?
|
| Quality Improvement | 6 | 2020 | 851 | 0.710 |
Why?
|
| Adult | 80 | 2023 | 77950 | 0.700 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2022 | 170 | 0.690 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2022 | 600 | 0.680 |
Why?
|
| Follow-Up Studies | 37 | 2022 | 14889 | 0.680 |
Why?
|
| Cohort Studies | 19 | 2022 | 9244 | 0.670 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 97 | 0.670 |
Why?
|
| Salvage Therapy | 7 | 2023 | 2054 | 0.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2023 | 15862 | 0.660 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 140 | 0.650 |
Why?
|
| Postoperative Complications | 20 | 2023 | 5542 | 0.650 |
Why?
|
| Pelvic Exenteration | 2 | 2017 | 108 | 0.640 |
Why?
|
| Carcinoma, Squamous Cell | 13 | 2023 | 5437 | 0.630 |
Why?
|
| Health Services Needs and Demand | 2 | 2019 | 244 | 0.630 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2021 | 716 | 0.620 |
Why?
|
| Hospitals, High-Volume | 2 | 2017 | 77 | 0.620 |
Why?
|
| Liver Neoplasms | 11 | 2023 | 4557 | 0.620 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 160 | 0.610 |
Why?
|
| Antineoplastic Protocols | 1 | 2017 | 33 | 0.610 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2017 | 49 | 0.610 |
Why?
|
| Aged, 80 and over | 43 | 2021 | 29902 | 0.610 |
Why?
|
| Mesenteric Artery, Inferior | 1 | 2017 | 6 | 0.600 |
Why?
|
| Health Care Reform | 1 | 2017 | 68 | 0.600 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2016 | 5 | 0.590 |
Why?
|
| Disease-Free Survival | 22 | 2023 | 10001 | 0.580 |
Why?
|
| Patient Care Management | 1 | 2017 | 94 | 0.570 |
Why?
|
| Survival Analysis | 20 | 2020 | 9180 | 0.570 |
Why?
|
| Attitude to Health | 1 | 2019 | 465 | 0.550 |
Why?
|
| Fluorouracil | 15 | 2023 | 1944 | 0.540 |
Why?
|
| Delivery of Health Care | 5 | 2024 | 860 | 0.540 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 475 | 0.540 |
Why?
|
| Dissection | 4 | 2021 | 156 | 0.540 |
Why?
|
| Neoplasm, Residual | 5 | 2015 | 1656 | 0.530 |
Why?
|
| DNA Mismatch Repair | 4 | 2023 | 268 | 0.530 |
Why?
|
| Neoplasm Metastasis | 11 | 2021 | 5112 | 0.520 |
Why?
|
| Time Factors | 25 | 2020 | 12926 | 0.510 |
Why?
|
| Age Factors | 15 | 2020 | 5377 | 0.510 |
Why?
|
| Organ Transplantation | 3 | 2020 | 191 | 0.510 |
Why?
|
| Induction Chemotherapy | 2 | 2017 | 669 | 0.500 |
Why?
|
| Young Adult | 27 | 2024 | 21445 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2022 | 1303 | 0.490 |
Why?
|
| Antineoplastic Agents | 12 | 2022 | 14289 | 0.490 |
Why?
|
| Hospitals | 1 | 2017 | 485 | 0.480 |
Why?
|
| Drug Discovery | 1 | 2016 | 324 | 0.470 |
Why?
|
| Hepatectomy | 7 | 2023 | 1011 | 0.470 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 104 | 0.470 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2013 | 20 | 0.470 |
Why?
|
| Appendiceal Neoplasms | 2 | 2013 | 234 | 0.470 |
Why?
|
| Anal Canal | 8 | 2023 | 238 | 0.470 |
Why?
|
| Insurance Coverage | 3 | 2022 | 256 | 0.460 |
Why?
|
| Cooperative Behavior | 2 | 2017 | 313 | 0.460 |
Why?
|
| Quality of Health Care | 1 | 2018 | 621 | 0.460 |
Why?
|
| Population Surveillance | 4 | 2018 | 627 | 0.460 |
Why?
|
| Multivariate Analysis | 12 | 2015 | 4298 | 0.460 |
Why?
|
| Neoplasm Grading | 8 | 2018 | 1742 | 0.450 |
Why?
|
| Health Status Disparities | 2 | 2021 | 291 | 0.450 |
Why?
|
| Life Expectancy | 1 | 2013 | 129 | 0.440 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2022 | 5319 | 0.440 |
Why?
|
| Anastomosis, Surgical | 2 | 2013 | 371 | 0.430 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 573 | 0.430 |
Why?
|
| Risk Assessment | 13 | 2021 | 6869 | 0.420 |
Why?
|
| Jejunal Neoplasms | 1 | 2011 | 34 | 0.420 |
Why?
|
| Fecal Incontinence | 2 | 2023 | 85 | 0.420 |
Why?
|
| Ileal Neoplasms | 1 | 2011 | 47 | 0.410 |
Why?
|
| Radiotherapy | 6 | 2015 | 1824 | 0.400 |
Why?
|
| Prospective Studies | 18 | 2022 | 12873 | 0.400 |
Why?
|
| Organ Sparing Treatments | 5 | 2023 | 277 | 0.390 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 502 | 0.390 |
Why?
|
| Nomograms | 1 | 2013 | 313 | 0.390 |
Why?
|
| Duodenal Neoplasms | 1 | 2011 | 138 | 0.390 |
Why?
|
| Healthcare Disparities | 4 | 2022 | 598 | 0.380 |
Why?
|
| Colorectal Surgery | 3 | 2022 | 32 | 0.370 |
Why?
|
| Mycophenolic Acid | 2 | 2000 | 148 | 0.360 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2010 | 70 | 0.360 |
Why?
|
| Lung Neoplasms | 7 | 2022 | 11538 | 0.360 |
Why?
|
| Mastectomy, Simple | 1 | 2010 | 58 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 7 | 2018 | 2403 | 0.350 |
Why?
|
| Logistic Models | 6 | 2020 | 3441 | 0.350 |
Why?
|
| Breast Neoplasms | 6 | 2022 | 15694 | 0.340 |
Why?
|
| Guideline Adherence | 4 | 2015 | 636 | 0.340 |
Why?
|
| ras Proteins | 1 | 2013 | 770 | 0.340 |
Why?
|
| Survivors | 5 | 2022 | 1031 | 0.340 |
Why?
|
| Telemedicine | 3 | 2022 | 471 | 0.340 |
Why?
|
| Intestinal Neoplasms | 1 | 2010 | 189 | 0.330 |
Why?
|
| Graft Rejection | 3 | 2002 | 834 | 0.330 |
Why?
|
| Health Status Indicators | 1 | 2009 | 224 | 0.330 |
Why?
|
| Proctoscopy | 2 | 2012 | 17 | 0.320 |
Why?
|
| Secondary Prevention | 1 | 2010 | 329 | 0.310 |
Why?
|
| Pneumoperitoneum | 1 | 2007 | 17 | 0.310 |
Why?
|
| Research Design | 4 | 2017 | 1544 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2022 | 7551 | 0.310 |
Why?
|
| Immunoglobulin G | 2 | 2002 | 1021 | 0.310 |
Why?
|
| Videoconferencing | 2 | 2018 | 56 | 0.300 |
Why?
|
| Databases, Factual | 8 | 2022 | 2218 | 0.300 |
Why?
|
| Prostatic Neoplasms | 6 | 2023 | 5767 | 0.300 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 1323 | 0.300 |
Why?
|
| Decision Support Techniques | 4 | 2021 | 622 | 0.300 |
Why?
|
| Precision Medicine | 2 | 2019 | 1154 | 0.290 |
Why?
|
| Intestine, Small | 1 | 2010 | 499 | 0.290 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2020 | 2231 | 0.290 |
Why?
|
| Health Services Research | 3 | 2022 | 233 | 0.290 |
Why?
|
| Ligation | 2 | 2017 | 193 | 0.290 |
Why?
|
| Adolescent | 17 | 2024 | 31252 | 0.280 |
Why?
|
| Sirolimus | 2 | 2000 | 814 | 0.280 |
Why?
|
| Patient Participation | 2 | 2021 | 446 | 0.280 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.280 |
Why?
|
| Aftercare | 2 | 2018 | 259 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 3981 | 0.270 |
Why?
|
| Laparotomy | 2 | 2018 | 211 | 0.270 |
Why?
|
| Re-Irradiation | 2 | 2018 | 163 | 0.270 |
Why?
|
| Odds Ratio | 5 | 2015 | 2316 | 0.270 |
Why?
|
| Comparative Effectiveness Research | 3 | 2018 | 126 | 0.270 |
Why?
|
| Texas | 8 | 2019 | 6311 | 0.260 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 3719 | 0.260 |
Why?
|
| Organoplatinum Compounds | 4 | 2017 | 702 | 0.260 |
Why?
|
| Kidney Transplantation | 5 | 2003 | 755 | 0.260 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2016 | 551 | 0.260 |
Why?
|
| Colonic Diseases | 1 | 2005 | 71 | 0.260 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 4892 | 0.250 |
Why?
|
| Medicare | 3 | 2015 | 860 | 0.250 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2012 | 1415 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2013 | 3251 | 0.250 |
Why?
|
| Leucovorin | 4 | 2023 | 332 | 0.240 |
Why?
|
| Immunosuppressive Agents | 2 | 2000 | 1375 | 0.240 |
Why?
|
| Preoperative Care | 6 | 2023 | 1529 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2488 | 0.240 |
Why?
|
| Calcineurin Inhibitors | 2 | 2000 | 68 | 0.230 |
Why?
|
| Propensity Score | 2 | 2018 | 750 | 0.230 |
Why?
|
| Genetic Testing | 4 | 2022 | 1589 | 0.230 |
Why?
|
| Medical Errors | 2 | 2016 | 219 | 0.230 |
Why?
|
| Calcineurin | 2 | 2000 | 128 | 0.230 |
Why?
|
| Feasibility Studies | 3 | 2019 | 2292 | 0.230 |
Why?
|
| Insurance | 1 | 2023 | 15 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 4 | 2013 | 5061 | 0.220 |
Why?
|
| Medical Overuse | 2 | 2020 | 45 | 0.220 |
Why?
|
| Expert Testimony | 2 | 2020 | 90 | 0.220 |
Why?
|
| Liver Transplantation | 2 | 2002 | 1112 | 0.220 |
Why?
|
| Disease Management | 3 | 2017 | 1052 | 0.220 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 1258 | 0.210 |
Why?
|
| Electrocoagulation | 1 | 2002 | 65 | 0.210 |
Why?
|
| Patient Readmission | 3 | 2015 | 548 | 0.210 |
Why?
|
| Carcinoembryonic Antigen | 3 | 2018 | 222 | 0.210 |
Why?
|
| Age of Onset | 4 | 2018 | 827 | 0.210 |
Why?
|
| CD40 Antigens | 1 | 2002 | 104 | 0.200 |
Why?
|
| Incidence | 7 | 2018 | 5673 | 0.200 |
Why?
|
| Sex Factors | 6 | 2013 | 2139 | 0.200 |
Why?
|
| Oncologists | 1 | 2024 | 134 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 945 | 0.200 |
Why?
|
| Health Services Accessibility | 3 | 2014 | 761 | 0.200 |
Why?
|
| Tissue and Organ Procurement | 2 | 2003 | 233 | 0.200 |
Why?
|
| Patient Care Planning | 1 | 2023 | 297 | 0.200 |
Why?
|
| Risk Factors | 14 | 2018 | 17523 | 0.190 |
Why?
|
| Abdomen | 2 | 2013 | 332 | 0.190 |
Why?
|
| Patient Care Team | 3 | 2023 | 795 | 0.190 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2000 | 186 | 0.190 |
Why?
|
| Habits | 1 | 2020 | 36 | 0.190 |
Why?
|
| Meta-Analysis as Topic | 2 | 2019 | 276 | 0.180 |
Why?
|
| Defecation | 2 | 2023 | 58 | 0.180 |
Why?
|
| Ovariectomy | 2 | 2012 | 330 | 0.180 |
Why?
|
| Radiotherapy Dosage | 6 | 2013 | 3842 | 0.180 |
Why?
|
| Social Class | 1 | 2021 | 310 | 0.180 |
Why?
|
| Colostomy | 2 | 2017 | 70 | 0.180 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2015 | 469 | 0.180 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 250 | 0.180 |
Why?
|
| Capecitabine | 7 | 2019 | 388 | 0.180 |
Why?
|
| Medicaid | 1 | 2022 | 279 | 0.170 |
Why?
|
| Fluorescein Angiography | 1 | 2020 | 139 | 0.170 |
Why?
|
| Coloring Agents | 1 | 2020 | 234 | 0.170 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 1085 | 0.170 |
Why?
|
| Indocyanine Green | 1 | 2020 | 117 | 0.170 |
Why?
|
| Health Care Rationing | 1 | 2020 | 94 | 0.170 |
Why?
|
| Pelvic Floor | 1 | 2019 | 48 | 0.170 |
Why?
|
| Ventricular Function, Right | 1 | 2020 | 111 | 0.170 |
Why?
|
| Tacrolimus | 1 | 2000 | 335 | 0.170 |
Why?
|
| Sacrum | 2 | 2010 | 132 | 0.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2022 | 2104 | 0.170 |
Why?
|
| Bevacizumab | 5 | 2017 | 938 | 0.160 |
Why?
|
| Surveys and Questionnaires | 6 | 2024 | 5687 | 0.160 |
Why?
|
| Carcinoma in Situ | 1 | 2002 | 487 | 0.160 |
Why?
|
| Occupational Injuries | 1 | 2018 | 18 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 2278 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 524 | 0.160 |
Why?
|
| Touch Perception | 1 | 2018 | 20 | 0.160 |
Why?
|
| Pancreatectomy | 2 | 2013 | 652 | 0.160 |
Why?
|
| Patient Preference | 2 | 2021 | 218 | 0.160 |
Why?
|
| Mutation | 3 | 2017 | 15179 | 0.160 |
Why?
|
| Cause of Death | 2 | 2013 | 752 | 0.160 |
Why?
|
| Camptothecin | 2 | 2017 | 517 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 289 | 0.160 |
Why?
|
| Western World | 1 | 2017 | 8 | 0.150 |
Why?
|
| Perineum | 1 | 2018 | 107 | 0.150 |
Why?
|
| Interviews as Topic | 1 | 2019 | 497 | 0.150 |
Why?
|
| Portal Vein | 1 | 2020 | 355 | 0.150 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2017 | 78 | 0.150 |
Why?
|
| Decision Making | 2 | 2022 | 1287 | 0.150 |
Why?
|
| Prosthesis Implantation | 1 | 2020 | 263 | 0.150 |
Why?
|
| Myocutaneous Flap | 1 | 2017 | 30 | 0.150 |
Why?
|
| Epidemiological Monitoring | 1 | 2017 | 73 | 0.150 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 671 | 0.150 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2016 | 17 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 306 | 0.150 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 211 | 0.150 |
Why?
|
| Microbiota | 1 | 2023 | 547 | 0.150 |
Why?
|
| Japan | 1 | 2017 | 227 | 0.150 |
Why?
|
| Melanoma | 4 | 2020 | 5317 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 1048 | 0.140 |
Why?
|
| Deoxycytidine | 5 | 2013 | 1353 | 0.140 |
Why?
|
| Urinary Diversion | 1 | 2017 | 69 | 0.140 |
Why?
|
| Mesenteric Arteries | 1 | 2016 | 55 | 0.140 |
Why?
|
| Pelvic Neoplasms | 1 | 2018 | 189 | 0.140 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 122 | 0.140 |
Why?
|
| Gene Expression | 3 | 2020 | 3570 | 0.140 |
Why?
|
| Value-Based Purchasing | 1 | 2016 | 15 | 0.140 |
Why?
|
| Postoperative Period | 2 | 2018 | 665 | 0.140 |
Why?
|
| Microsomes, Liver | 1 | 2016 | 115 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 2 | 2018 | 1350 | 0.140 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2017 | 108 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 2 | 2012 | 634 | 0.140 |
Why?
|
| Gastroenterologists | 1 | 2016 | 21 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2016 | 221 | 0.140 |
Why?
|
| Registries | 5 | 2018 | 2170 | 0.140 |
Why?
|
| Age Distribution | 2 | 2015 | 698 | 0.130 |
Why?
|
| Frail Elderly | 1 | 2016 | 118 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 301 | 0.130 |
Why?
|
| Consensus | 4 | 2022 | 978 | 0.130 |
Why?
|
| Hypolipidemic Agents | 2 | 2010 | 190 | 0.130 |
Why?
|
| Hemodynamics | 1 | 2020 | 935 | 0.130 |
Why?
|
| Music | 1 | 2015 | 36 | 0.130 |
Why?
|
| Checklist | 1 | 2016 | 122 | 0.130 |
Why?
|
| Professional Role | 1 | 2015 | 78 | 0.130 |
Why?
|
| Forecasting | 1 | 2018 | 694 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2021 | 1270 | 0.130 |
Why?
|
| Mentoring | 1 | 2016 | 87 | 0.130 |
Why?
|
| Medical Staff, Hospital | 1 | 2015 | 118 | 0.130 |
Why?
|
| Kidney | 2 | 2000 | 2146 | 0.130 |
Why?
|
| Dogs | 1 | 2016 | 1155 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 610 | 0.130 |
Why?
|
| Nitrites | 1 | 1994 | 61 | 0.130 |
Why?
|
| Reoperation | 3 | 2020 | 1382 | 0.120 |
Why?
|
| Morbidity | 2 | 2014 | 397 | 0.120 |
Why?
|
| Operating Rooms | 1 | 2015 | 122 | 0.120 |
Why?
|
| Graft Survival | 3 | 2003 | 1062 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2002 | 1616 | 0.120 |
Why?
|
| Enterostomy | 1 | 2014 | 6 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2020 | 5539 | 0.120 |
Why?
|
| Cisplatin | 3 | 2022 | 2432 | 0.120 |
Why?
|
| Surgeons | 1 | 2021 | 519 | 0.120 |
Why?
|
| Pandemics | 2 | 2022 | 1559 | 0.120 |
Why?
|
| Surgical Wound Infection | 2 | 2022 | 450 | 0.120 |
Why?
|
| Lipoproteins, LDL | 1 | 1994 | 163 | 0.120 |
Why?
|
| Exosomes | 1 | 2016 | 253 | 0.120 |
Why?
|
| Comorbidity | 2 | 2018 | 2352 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2015 | 495 | 0.120 |
Why?
|
| Death Certificates | 1 | 2013 | 17 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2017 | 739 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 748 | 0.110 |
Why?
|
| Pneumonectomy | 1 | 2018 | 831 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2015 | 756 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2023 | 799 | 0.110 |
Why?
|
| ROC Curve | 2 | 2016 | 1183 | 0.110 |
Why?
|
| Receptors, Estrogen | 3 | 2022 | 2086 | 0.110 |
Why?
|
| Endosonography | 2 | 2015 | 536 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2017 | 661 | 0.110 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 489 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 5159 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 902 | 0.110 |
Why?
|
| Internet | 2 | 2009 | 706 | 0.100 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2012 | 43 | 0.100 |
Why?
|
| Radiology | 1 | 2017 | 434 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Decision Trees | 1 | 2012 | 178 | 0.100 |
Why?
|
| Health Resources | 1 | 2013 | 168 | 0.100 |
Why?
|
| Fatigue | 1 | 2018 | 1239 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Reimbursement Mechanisms | 1 | 2012 | 78 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 275 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2588 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2015 | 1546 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2017 | 787 | 0.100 |
Why?
|
| Students, Medical | 1 | 2016 | 399 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1910 | 0.100 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 2010 | 25 | 0.100 |
Why?
|
| Communication | 1 | 2017 | 876 | 0.090 |
Why?
|
| Nitric Oxide | 1 | 1994 | 644 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 4367 | 0.090 |
Why?
|
| Pain Management | 2 | 2020 | 668 | 0.090 |
Why?
|
| Documentation | 1 | 2012 | 207 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 294 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 1371 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2012 | 228 | 0.090 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 1171 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 4938 | 0.090 |
Why?
|
| Selection Bias | 1 | 2010 | 50 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 806 | 0.090 |
Why?
|
| Proteomics | 1 | 2017 | 1380 | 0.090 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.090 |
Why?
|
| Preoperative Period | 2 | 2023 | 344 | 0.090 |
Why?
|
| Genetic Markers | 2 | 2019 | 974 | 0.090 |
Why?
|
| Tumor Burden | 4 | 2020 | 1987 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 4314 | 0.090 |
Why?
|
| Anus Diseases | 1 | 2009 | 29 | 0.090 |
Why?
|
| HIV Infections | 1 | 2002 | 2134 | 0.090 |
Why?
|
| Rectal Diseases | 1 | 2009 | 55 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1225 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 918 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 1870 | 0.080 |
Why?
|
| Metformin | 1 | 2013 | 378 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2010 | 2022 | 0.080 |
Why?
|
| Mucins | 1 | 2010 | 285 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2022 | 3341 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 586 | 0.080 |
Why?
|
| Chordoma | 1 | 2010 | 163 | 0.080 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2012 | 690 | 0.080 |
Why?
|
| Intestinal Obstruction | 1 | 2010 | 202 | 0.080 |
Why?
|
| Recurrence | 4 | 2024 | 4758 | 0.080 |
Why?
|
| Peritoneum | 2 | 2022 | 150 | 0.080 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 292 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2009 | 132 | 0.080 |
Why?
|
| Rosaniline Dyes | 1 | 2007 | 108 | 0.080 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2008 | 169 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2014 | 977 | 0.070 |
Why?
|
| Benchmarking | 2 | 2021 | 273 | 0.070 |
Why?
|
| Radiation Injuries | 2 | 2017 | 1411 | 0.070 |
Why?
|
| Palliative Care | 3 | 2014 | 2037 | 0.070 |
Why?
|
| Fellowships and Scholarships | 2 | 2021 | 390 | 0.070 |
Why?
|
| Keratins | 1 | 2007 | 330 | 0.070 |
Why?
|
| Endoscopy | 2 | 2023 | 479 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1331 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 1085 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2010 | 611 | 0.070 |
Why?
|
| Heart Failure | 1 | 2020 | 2516 | 0.070 |
Why?
|
| Apolipoproteins B | 3 | 2010 | 106 | 0.070 |
Why?
|
| Rats, Inbred Lew | 2 | 2002 | 113 | 0.070 |
Why?
|
| Triglycerides | 2 | 2010 | 603 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2010 | 2307 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 2576 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2009 | 479 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 1165 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4320 | 0.070 |
Why?
|
| Curriculum | 2 | 2021 | 860 | 0.060 |
Why?
|
| Pain | 2 | 2010 | 1658 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 4654 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 609 | 0.060 |
Why?
|
| Receptors, Progesterone | 2 | 2022 | 1392 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2010 | 631 | 0.060 |
Why?
|
| Obesity | 1 | 2017 | 2884 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 2 | 2020 | 383 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 363 | 0.060 |
Why?
|
| Hospitalization | 1 | 2013 | 2083 | 0.060 |
Why?
|
| Biopsy | 2 | 2023 | 3443 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 3472 | 0.060 |
Why?
|
| Stents | 1 | 2010 | 1096 | 0.060 |
Why?
|
| Spain | 1 | 2003 | 113 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 510 | 0.060 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2006 | 221 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2006 | 1299 | 0.060 |
Why?
|
| Carboplatin | 2 | 2017 | 823 | 0.060 |
Why?
|
| Apolipoprotein B-100 | 2 | 2010 | 30 | 0.060 |
Why?
|
| Prosthesis Design | 2 | 2020 | 749 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2016 | 2947 | 0.060 |
Why?
|
| Cadaver | 1 | 2003 | 237 | 0.060 |
Why?
|
| Isoquinolines | 1 | 2003 | 116 | 0.060 |
Why?
|
| Rats, Inbred ACI | 1 | 2002 | 11 | 0.060 |
Why?
|
| Rats, Inbred BN | 1 | 2002 | 34 | 0.050 |
Why?
|
| Treatment Failure | 4 | 2008 | 1391 | 0.050 |
Why?
|
| Interprofessional Relations | 2 | 2015 | 213 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1362 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1046 | 0.050 |
Why?
|
| Operative Time | 1 | 2023 | 217 | 0.050 |
Why?
|
| Kidney Cortex | 1 | 2001 | 35 | 0.050 |
Why?
|
| Algorithms | 1 | 2013 | 3890 | 0.050 |
Why?
|
| Colonoscopy | 2 | 2016 | 518 | 0.050 |
Why?
|
| Netherlands | 1 | 2021 | 83 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 10331 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2002 | 173 | 0.050 |
Why?
|
| Parity | 1 | 2001 | 139 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 210 | 0.050 |
Why?
|
| Animals | 6 | 2016 | 59536 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4849 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2001 | 221 | 0.050 |
Why?
|
| Mitomycin | 1 | 2022 | 208 | 0.050 |
Why?
|
| Quality Control | 2 | 2012 | 457 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 225 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 2 | 2022 | 2518 | 0.050 |
Why?
|
| Living Donors | 1 | 2001 | 171 | 0.050 |
Why?
|
| Contraindications | 1 | 2000 | 150 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2001 | 175 | 0.050 |
Why?
|
| Prednisolone | 1 | 2000 | 123 | 0.050 |
Why?
|
| Cell Line | 3 | 2016 | 5114 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 651 | 0.050 |
Why?
|
| Cholecystostomy | 1 | 2000 | 9 | 0.050 |
Why?
|
| Transgenes | 1 | 2002 | 557 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 40 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2000 | 193 | 0.050 |
Why?
|
| Cholecystitis | 1 | 2000 | 52 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 403 | 0.040 |
Why?
|
| Cholesterol | 1 | 2003 | 658 | 0.040 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2000 | 68 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 64 | 0.040 |
Why?
|
| Rats | 3 | 2003 | 6086 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2019 | 73 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 4971 | 0.040 |
Why?
|
| Triazoles | 1 | 2003 | 617 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1351 | 0.040 |
Why?
|
| Community Networks | 1 | 2018 | 45 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 233 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 100 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 350 | 0.040 |
Why?
|
| Self Concept | 1 | 2019 | 211 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 270 | 0.040 |
Why?
|
| Intention | 1 | 2018 | 109 | 0.040 |
Why?
|
| Radiodermatitis | 1 | 2017 | 75 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2019 | 272 | 0.040 |
Why?
|
| Community Health Workers | 1 | 2017 | 57 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 155 | 0.040 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 101 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2017 | 122 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2018 | 660 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2000 | 629 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2002 | 1459 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 543 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 678 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2018 | 226 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 703 | 0.040 |
Why?
|
| Sulfasalazine | 1 | 2016 | 16 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2018 | 334 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 980 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 2016 | 47 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 672 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 2017 | 188 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 2843 | 0.030 |
Why?
|
| Liquid Biopsy | 1 | 2016 | 158 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 899 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 1443 | 0.030 |
Why?
|
| Nurse Practitioners | 1 | 2016 | 63 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 43 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 870 | 0.030 |
Why?
|
| Minority Groups | 1 | 2017 | 322 | 0.030 |
Why?
|
| Butylated Hydroxytoluene | 1 | 1994 | 13 | 0.030 |
Why?
|
| Polyurethanes | 1 | 2014 | 36 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 200 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 1994 | 75 | 0.030 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2016 | 94 | 0.030 |
Why?
|
| Geography | 1 | 2014 | 140 | 0.030 |
Why?
|
| beta Carotene | 1 | 1994 | 76 | 0.030 |
Why?
|
| Superoxides | 1 | 1994 | 211 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1274 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2017 | 514 | 0.030 |
Why?
|
| Video Recording | 1 | 2016 | 267 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 85 | 0.030 |
Why?
|
| Carotenoids | 1 | 1994 | 96 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 1248 | 0.030 |
Why?
|
| Attention | 1 | 2015 | 281 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 686 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 256 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2013 | 13 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 1994 | 266 | 0.030 |
Why?
|
| Xeroderma Pigmentosum | 1 | 1993 | 70 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 585 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 14551 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 1037 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 493 | 0.030 |
Why?
|
| Organizations | 1 | 2013 | 23 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2014 | 95 | 0.030 |
Why?
|
| Rabbits | 1 | 1994 | 957 | 0.030 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 493 | 0.030 |
Why?
|
| Health Priorities | 1 | 2013 | 40 | 0.030 |
Why?
|
| Income | 1 | 2014 | 222 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 467 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 1994 | 717 | 0.030 |
Why?
|
| Travel | 1 | 2014 | 190 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 397 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 6009 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 833 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 388 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 226 | 0.030 |
Why?
|
| Gels | 1 | 2012 | 105 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 1994 | 1008 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2012 | 117 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2012 | 259 | 0.020 |
Why?
|
| Lung | 1 | 2022 | 3151 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 236 | 0.020 |
Why?
|
| Apolipoprotein B-48 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Lipoproteins, HDL3 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2015 | 667 | 0.020 |
Why?
|
| Triolein | 1 | 2010 | 4 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 915 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2012 | 217 | 0.020 |
Why?
|
| Colon, Sigmoid | 1 | 2010 | 42 | 0.020 |
Why?
|
| Polyradiculopathy | 1 | 2010 | 13 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1209 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1290 | 0.020 |
Why?
|
| Oxygen | 1 | 1994 | 754 | 0.020 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2010 | 47 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2010 | 144 | 0.020 |
Why?
|
| Marital Status | 1 | 2010 | 98 | 0.020 |
Why?
|
| Neutrophils | 1 | 1994 | 835 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 2012 | 280 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2010 | 65 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 884 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2010 | 178 | 0.020 |
Why?
|
| Foreign-Body Migration | 1 | 2010 | 117 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2010 | 232 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 341 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2203 | 0.020 |
Why?
|
| Life Style | 1 | 2013 | 612 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 515 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 310 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 7548 | 0.020 |
Why?
|
| Artifacts | 1 | 2012 | 532 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 627 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 923 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 503 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 4821 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 237 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2019 | 1375 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 129 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 684 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 351 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 452 | 0.020 |
Why?
|
| Child | 2 | 2024 | 29154 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 2738 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 1021 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 1996 | 0.020 |
Why?
|
| Rehabilitation Nursing | 1 | 2007 | 9 | 0.020 |
Why?
|
| Seminal Vesicles | 1 | 2007 | 152 | 0.020 |
Why?
|
| Surgical Stomas | 1 | 2007 | 20 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2010 | 435 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 866 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 447 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 103 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 925 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2007 | 114 | 0.020 |
Why?
|
| Access to Information | 1 | 2007 | 65 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 177 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 2027 | 0.020 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2006 | 56 | 0.020 |
Why?
|
| DNA Damage | 1 | 1993 | 1954 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 446 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 465 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 1472 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 2927 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2007 | 575 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 552 | 0.010 |
Why?
|
| Remission Induction | 1 | 2010 | 3569 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 2003 | 84 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 289 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2007 | 962 | 0.010 |
Why?
|
| Phospholipids | 1 | 2003 | 177 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6100 | 0.010 |
Why?
|
| Pyridines | 1 | 2009 | 1244 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 6682 | 0.010 |
Why?
|
| Raffinose | 1 | 2001 | 6 | 0.010 |
Why?
|
| Organ Preservation Solutions | 1 | 2001 | 20 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2001 | 55 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8873 | 0.010 |
Why?
|
| Allopurinol | 1 | 2001 | 54 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2001 | 133 | 0.010 |
Why?
|
| Fathers | 1 | 2001 | 68 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 5710 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2003 | 448 | 0.010 |
Why?
|
| Spouses | 1 | 2001 | 134 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2000 | 173 | 0.010 |
Why?
|
| Anesthesia, Local | 1 | 2000 | 66 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 447 | 0.010 |
Why?
|
| Adenosine | 1 | 2001 | 289 | 0.010 |
Why?
|
| Glutathione | 1 | 2001 | 368 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 2063 | 0.010 |
Why?
|
| Ischemia | 1 | 2001 | 391 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 2000 | 239 | 0.010 |
Why?
|
| Mothers | 1 | 2001 | 410 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2003 | 1081 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 1204 | 0.010 |
Why?
|
| Mice | 2 | 2010 | 34495 | 0.010 |
Why?
|
| Insulin | 1 | 2001 | 1454 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 3536 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 3639 | 0.010 |
Why?
|
| Acute Disease | 1 | 2000 | 2422 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1993 | 157 | 0.010 |
Why?
|
| Liver | 1 | 2003 | 2961 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 568 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2001 | 1054 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1993 | 549 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 6150 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1993 | 575 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1993 | 1643 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 7573 | 0.010 |
Why?
|